Placebo to match sirukumab

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Giant Cell ArteritisPolymyalgia Rheumatica

Phase 3

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

TerminatedNCT02531633

GlaxoSmithKlineGiant Cell Arteritis

Start: 2015-10-16End: 2018-03-21Updated: 2019-07-31

Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica

WithdrawnNCT02899026

GlaxoSmithKlinePolymyalgia Rheumatica

Start: 2018-03-15End: 2021-08-26Updated: 2017-11-20

Related Papers

A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis.

2020-08-2531 citations